Iron Chelation and Glucose Metabolism
in [Fibromyalgia]
|
From: ironjustice on 13 Jun 2008 19:39 On Jun 13, 3:06 pm, "Paul T. Holland" <pholl...(a)bellatlantic.net> wrote:long winded whack << Br J Haematol. 2006 Aug;134(4):438-44. Epub 2006 Jul 4.Related Articles, Links Comment in: Br J Haematol. 2006 Oct;135(2):271-2. Effect of enhanced iron chelation therapy on glucose metabolism in patients with beta-thalassaemia major. Farmaki K, Angelopoulos N, Anagnostopoulos G, Gotsis E, Rombopoulos G, Tolis G. Haematological Department, Korinthos General Hospital, Korinthos, Greece. Recently introduced chelation regimens that combine deferoxamine (DFO) and deferiprone have been shown to have greater efficacy in promoting iron excretion than either chelator alone and have been associated with rapid reduction of the iron load in the heart and liver, and with reversal of cardiac dysfunction. It is unclear whether this combined therapy could be associated with a reduction in iron load or decline in the severity of iron-induced endocrinopathies. Starting in January 2001, 42 patients with beta-thalassaemia major, previously maintained on subcutaneous DFO only, were switched to combined treatment with DFO and deferiprone. The primary endpoint was to investigate the effects of this therapy on the glucose metabolism characteristics of this population. Combination therapy markedly decreased ferritin levels (638 +/- 1345 vs. 2991 +/- 2093 microg/l, P < 0.001). Glucose responses were improved at all times during an oral glucose tolerance test, particularly in patients in early stages of glucose intolerance. Glucose quantitative secretion also decreased significantly with combined therapy, while no significant change occurred in insulin levels in any group. Insulin secretion, according to the homeostasis assessment model, markedly increased in all groups, while overall reduction in insulin sensitivity did not reach statistical significance. This study showed that the combination of DFO and deferiprone was associated with an improvement in liver iron deposition and glucose intolerance. PMID: 16822284 [PubMed - indexed for MEDLINE] Who loves ya. Tom Jesus Was A Vegetarian! http://tinyurl.com/2r2nkh Man Is A Herbivore! http://tinyurl.com/a3cc3 DEAD PEOPLE WALKING http://tinyurl.com/zk9fk
From: ironjustice on 13 Jun 2008 19:41 On Jun 13, 3:32 pm, J666 <j...(a)nowhere.com> wrote: how many different bacteria in sht << Br J Haematol. 2006 Aug;134(4):438-44. Epub 2006 Jul 4.Related Articles, Links Comment in: Br J Haematol. 2006 Oct;135(2):271-2. Effect of enhanced iron chelation therapy on glucose metabolism in patients with beta-thalassaemia major. Farmaki K, Angelopoulos N, Anagnostopoulos G, Gotsis E, Rombopoulos G, Tolis G. Haematological Department, Korinthos General Hospital, Korinthos, Greece. Recently introduced chelation regimens that combine deferoxamine (DFO) and deferiprone have been shown to have greater efficacy in promoting iron excretion than either chelator alone and have been associated with rapid reduction of the iron load in the heart and liver, and with reversal of cardiac dysfunction. It is unclear whether this combined therapy could be associated with a reduction in iron load or decline in the severity of iron-induced endocrinopathies. Starting in January 2001, 42 patients with beta-thalassaemia major, previously maintained on subcutaneous DFO only, were switched to combined treatment with DFO and deferiprone. The primary endpoint was to investigate the effects of this therapy on the glucose metabolism characteristics of this population. Combination therapy markedly decreased ferritin levels (638 +/- 1345 vs. 2991 +/- 2093 microg/l, P < 0.001). Glucose responses were improved at all times during an oral glucose tolerance test, particularly in patients in early stages of glucose intolerance. Glucose quantitative secretion also decreased significantly with combined therapy, while no significant change occurred in insulin levels in any group. Insulin secretion, according to the homeostasis assessment model, markedly increased in all groups, while overall reduction in insulin sensitivity did not reach statistical significance. This study showed that the combination of DFO and deferiprone was associated with an improvement in liver iron deposition and glucose intolerance. PMID: 16822284 [PubMed - indexed for MEDLINE] Who loves ya. Tom Jesus Was A Vegetarian! http://tinyurl.com/2r2nkh Man Is A Herbivore! http://tinyurl.com/a3cc3 DEAD PEOPLE WALKING http://tinyurl.com/zk9fk
From: Paul T. Holland on 13 Jun 2008 21:00 thanks tom every time you post it, it proves you wrong...by your own hand odd as it would appear, that must be what you want ironjustice wrote: > > On Jun 13, 3:06 pm, "Paul T. Holland" <pholl...(a)bellatlantic.net> > wrote:long winded whack << > > Br J Haematol. 2006 Aug;134(4):438-44. Epub 2006 Jul 4.Related > Articles, Links > Comment in: > Br J Haematol. 2006 Oct;135(2):271-2. > > Effect of enhanced iron chelation therapy on glucose metabolism in > patients with beta-thalassaemia major. > > Farmaki K, Angelopoulos N, Anagnostopoulos G, Gotsis E, Rombopoulos > G, > Tolis G. > > Haematological Department, Korinthos General Hospital, Korinthos, > Greece. > > Recently introduced chelation regimens that combine deferoxamine > (DFO) > and deferiprone have been shown to have greater efficacy in promoting > iron excretion than either chelator alone and have been associated > with rapid reduction of the iron load in the heart and liver, and > with > reversal of cardiac dysfunction. It is unclear whether this combined > therapy could be associated with a reduction in iron load or decline > in the severity of iron-induced endocrinopathies. Starting in January > 2001, 42 patients with beta-thalassaemia major, previously maintained > on subcutaneous DFO only, were switched to combined treatment with > DFO > and deferiprone. The primary endpoint was to investigate the effects > of this therapy on the glucose metabolism characteristics of this > population. Combination therapy markedly decreased ferritin levels > (638 +/- 1345 vs. 2991 +/- 2093 microg/l, P < 0.001). Glucose > responses were improved at all times during an oral glucose tolerance > test, particularly in patients in early stages of glucose > intolerance. > Glucose quantitative secretion also decreased significantly with > combined therapy, while no significant change occurred in insulin > levels in any group. Insulin secretion, according to the homeostasis > assessment model, markedly increased in all groups, while overall > reduction in insulin sensitivity did not reach statistical > significance. This study showed that the combination of DFO and > deferiprone was associated with an improvement in liver iron > deposition and glucose intolerance. > > PMID: 16822284 [PubMed - indexed for MEDLINE] > > Who loves ya. > Tom > > Jesus Was A Vegetarian! > http://tinyurl.com/2r2nkh > > Man Is A Herbivore! > http://tinyurl.com/a3cc3 > > DEAD PEOPLE WALKING > http://tinyurl.com/zk9fk
From: ironjustice on 13 Jun 2008 21:34 On Jun 13, 6:00 pm, "Paul T. Holland" <pholl...(a)bellatlantic.net> wrote:long winded whack << You can't seem to get the .. drift .. man .. YOU ARE A FKG WHACKJOB .. !! YOU ARE A FKG WHACKJOB .. !! YOU ARE A FKG WHACKJOB .. !! YOU ARE A FKG WHACKJOB .. !! YOU ARE A FKG WHACKJOB .. !! YOU ARE A FKG WHACKJOB .. !! Stay off my threads .. Who loves ya. Tom Jesus Was A Vegetarian! http://tinyurl.com/2r2nkh Man Is A Herbivore! http://tinyurl.com/a3cc3 DEAD PEOPLE WALKING http://tinyurl.com/zk9fk > thanks tom > > every time you post it, it proves you wrong...by your own hand > > odd as it would appear, that must be what you want > > > > ironjustice wrote: > > > On Jun 13, 3:06 pm, "Paul T. Holland" <pholl...(a)bellatlantic.net> > > wrote:long winded whack << > > > Br J Haematol. 2006 Aug;134(4):438-44. Epub 2006 Jul 4.Related > > Articles, Links > > Comment in: > > Br J Haematol. 2006 Oct;135(2):271-2. > > > Effect of enhanced iron chelation therapy on glucose metabolism in > > patients with beta-thalassaemia major. > > > Farmaki K, Angelopoulos N, Anagnostopoulos G, Gotsis E, Rombopoulos > > G, > > Tolis G. > > > Haematological Department, Korinthos General Hospital, Korinthos, > > Greece. > > > Recently introduced chelation regimens that combine deferoxamine > > (DFO) > > and deferiprone have been shown to have greater efficacy in promoting > > iron excretion than either chelator alone and have been associated > > with rapid reduction of the iron load in the heart and liver, and > > with > > reversal of cardiac dysfunction. It is unclear whether this combined > > therapy could be associated with a reduction in iron load or decline > > in the severity of iron-induced endocrinopathies. Starting in January > > 2001, 42 patients with beta-thalassaemia major, previously maintained > > on subcutaneous DFO only, were switched to combined treatment with > > DFO > > and deferiprone. The primary endpoint was to investigate the effects > > of this therapy on the glucose metabolism characteristics of this > > population. Combination therapy markedly decreased ferritin levels > > (638 +/- 1345 vs. 2991 +/- 2093 microg/l, P < 0.001). Glucose > > responses were improved at all times during an oral glucose tolerance > > test, particularly in patients in early stages of glucose > > intolerance. > > Glucose quantitative secretion also decreased significantly with > > combined therapy, while no significant change occurred in insulin > > levels in any group. Insulin secretion, according to the homeostasis > > assessment model, markedly increased in all groups, while overall > > reduction in insulin sensitivity did not reach statistical > > significance. This study showed that the combination of DFO and > > deferiprone was associated with an improvement in liver iron > > deposition and glucose intolerance. > > > PMID: 16822284 [PubMed - indexed for MEDLINE] > > > Who loves ya. > > Tom > > > Jesus Was A Vegetarian! > >http://tinyurl.com/2r2nkh > > > Man Is A Herbivore! > >http://tinyurl.com/a3cc3 > > > DEAD PEOPLE WALKING > >http://tinyurl.com/zk9fk- Hide quoted text - > > - Show quoted text -
From: ironjustice on 13 Jun 2008 22:01
On Jun 12, 8:55 pm, ironjustice <teamtan...(a)hotmail.com> wrote: Effect of enhanced iron chelation therapy << "Correlation of serum ferritin concentrations with 2-hour glucose concentration (top) in 538 nondiabetic persons and insulin sensitivity in 257 nondiabetic persons." http://www.annals.org/cgi/content/full/139/10/869-b?ct "Bloodletting improved glycemia and insulin sensitivity in patients with type 2 diabetes " from the Annals of Internal Medicine 11/18/03 Association of High Serum Ferritin Concentration with Glucose Intolerance and Insulin Resistance in Healthy People Background: Increasing evidence points to an association between increased body iron storage and type 2 diabetes mellitus, even outside the context of hemochromatosis (1, 2). A small intervention study provided preliminary evidence that bloodletting, which resulted in 50% reduction of serum ferritin concentrations, improved glycemia and insulin sensitivity in patients with type 2 diabetes (3). However, interpretation of mechanistic studies in patients with overt type 2 diabetes mellitus are complicated because glycemic control itself influences serum ferritin concentrations (glycosylated ferritin has a longer serum half-life) and primary effects on insulin sensitivity or ß-cell function can no longer be studied. Objective: To analyze the relationship between iron variables and glucose tolerance, insulin sensitivity, and ß-cell function in nondiabetic persons. Conclusion: It may become advisable to routinely screen for mildly elevated or even high-normal serum ferritin concentrations in the context of glucose intolerance. If prospective and interventional studies confirm an etiologic role of iron overload in the pathogenesis of insulin resistance and type 2 diabetes, reduced dietary iron intake, especially in men and postmenopausal women (9) with additional risk factors for type 2 diabetes, would appear to be a logical consequence. In the future, actively lowering body iron stores may become a tool in preventing type 2 diabetes in selected subgroups. Who loves ya. Tom Jesus Was A Vegetarian! http://tinyurl.com/2r2nkh Man Is A Herbivore! http://tinyurl.com/a3cc3 DEAD PEOPLE WALKING http://tinyurl.com/zk9fk > Br J Haematol. 2006 Aug;134(4):438-44. Epub 2006 Jul 4.Related > Articles, Links > Comment in: > Br J Haematol. 2006 Oct;135(2):271-2. > > Effect of enhanced iron chelation therapy on glucose metabolism in > patients with beta-thalassaemia major. > > Farmaki K, Angelopoulos N, Anagnostopoulos G, Gotsis E, Rombopoulos G, > Tolis G. > > Haematological Department, Korinthos General Hospital, Korinthos, > Greece. > > Recently introduced chelation regimens that combine deferoxamine (DFO) > and deferiprone have been shown to have greater efficacy in promoting > iron excretion than either chelator alone and have been associated > with rapid reduction of the iron load in the heart and liver, and with > reversal of cardiac dysfunction. It is unclear whether this combined > therapy could be associated with a reduction in iron load or decline > in the severity of iron-induced endocrinopathies. Starting in January > 2001, 42 patients with beta-thalassaemia major, previously maintained > on subcutaneous DFO only, were switched to combined treatment with DFO > and deferiprone. The primary endpoint was to investigate the effects > of this therapy on the glucose metabolism characteristics of this > population. Combination therapy markedly decreased ferritin levels > (638 +/- 1345 vs. 2991 +/- 2093 microg/l, P < 0.001). Glucose > responses were improved at all times during an oral glucose tolerance > test, particularly in patients in early stages of glucose intolerance. > Glucose quantitative secretion also decreased significantly with > combined therapy, while no significant change occurred in insulin > levels in any group. Insulin secretion, according to the homeostasis > assessment model, markedly increased in all groups, while overall > reduction in insulin sensitivity did not reach statistical > significance. This study showed that the combination of DFO and > deferiprone was associated with an improvement in liver iron > deposition and glucose intolerance. > > PMID: 16822284 [PubMed - indexed for MEDLINE] > > Who loves ya. > Tom > > Jesus Was A Vegetarian!http://tinyurl.com/2r2nkh > > Man Is A Herbivore!http://tinyurl.com/a3cc3 > > DEAD PEOPLE WALKINGhttp://tinyurl.com/zk9fk |